Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 5/20 | 0.44 |
| ▸ | AKR1C3 | P42330 | 4/20 | 0.44 |
| ▸ | AKR1C2 | P52895 | 4/20 | 0.44 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.44 |
| ▸ | TAS2R14 | Q9NYV8 | 1/20 | 0.44 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | CDK2 | P24941 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.38 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.38 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.37 |
| ▸ | CASR | P41180 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1633725 | 0.86 | RXRB (0.46) | PTGS2AKR1C3AKR1C2PTGS1TAS2R14 | |
| SCHEMBL16914511 | 0.80 | CA1 (0.55) | PTGS2MCL1ALDH1A1KDM4EHPGD | |
| SCHEMBL26979278 | 0.80 | AKR1C2 (0.44) | PTGS2AKR1C3AKR1C2PTGS1TAS2R14 | |
| SCHEMBL23141189 | 0.78 | PTGS2 (0.43) | PTGS2AKR1C3AKR1C2PTGS1TAS2R14 | |
| SCHEMBL21814272 | 0.78 | KEAP1 (0.58) | PTGS2AKR1C3AKR1C2PTGS1TAS2R14 | |
| SCHEMBL31046834 | 0.78 | WDR5 (0.40) | PTGS2AKR1C3AKR1C2PTGS1TAS2R14 | |
| SCHEMBL15123097 | 0.78 | ALDH1A1 (0.49) | PTGS2AKR1C3AKR1C2PTGS1TAS2R14 | |
| SCHEMBL22628276 | 0.76 | AKR1C2 (0.44) | PTGS2AKR1C3AKR1C2PTGS1TAS2R14 | |
| SCHEMBL20357366 | 0.76 | HDAC1 (0.40) | PTGS2AKR1C3AKR1C2PTGS1TAS2R14 | |
| SCHEMBL12392029 | 0.75 | SLC9A1 (0.49) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2807162-B1 | SUBSTITUTED PHENYLIMIDAZOPYRAZOLES AND USE THEREOF | Bayer Pharma AG (DE) | 2017-06-07 | — | — | EP | disclosed |
| US-9394309-B2 | Substituted phenylimidazopyrazoles and their use | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-07-19 | — | — | US | disclosed |
| US-20150005288-A1 | SUBSTITUTED PHENYLIMIDAZOPYRAZOLES AND USE THEREOF | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2015-01-01 | — | — | US | disclosed |
| US-20130190290-A1 | Substituted phenylimidazopyrazoles and their use | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-07-25 | — | — | US | disclosed |
| US-8404893-B2 | Pentafluorosulfanylbenzoylguanidines, processes for their preparation, their use as medicaments or diagnostic aids, and medicaments comprising them | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2013-03-26 | — | — | US | disclosed |
| US-20110306670-A1 | PENTAFLUOROSULFANYLBENZOYLGUANIDINES, PROCESSES FOR THEIR PREPARATION, THEIR USE AS MEDICAMENTS OR DIAGNOSTIC AIDS, AND MEDICAMENTS COMPRISING THEM | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2011-12-15 | — | — | US | disclosed |
| US-8008352-B2 | N-[2-Chloro-4-pentafluorosulfanylbenzoyl]guanidine; ischemia, reperfusion, arrythmia angina pectoris; inhibit the cellular sodium-proton antiporter (Na+/H+ exchanger, NHE); stability, longer half-life in vivo, high bioavailability | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2011-08-30 | — | — | US | disclosed |
| US-20080200553-A1 | PENTAFLUOROSULFANYLBENZOYLGUANIDINES, PROCESSES FOR THEIR PREPARATION, THEIR USE AS MEDICAMENTS OR DIAGNOSTIC AIDS, AND MEDICAMENTS COMPRISING THEM | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2008-08-21 | — | — | US | disclosed |
| US-7375138-B2 | Pentafluorosulfanylbenzoylguanidines, processes for their preparation, their use as medicaments or diagnostic aids, and medicaments comprising them | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2008-05-20 | — | — | US | disclosed |
| US-20030216476-A1 | Pentafluorosulfanylbenzoylguanidines, processes for their preparation, their use as medicaments or diagnostic aids, and medicaments comprising them | AVENTIS PHARMA DEUTSHCHLAND GMBH (DE) | 2003-11-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150005288-A1 | SUBSTITUTED PHENYLIMIDAZOPYRAZOLES AND USE THEREOF | VHL, FLT4, FLT1 | PTGS2 333/4885AKR1C3 2454/4885AKR1C2 2518/4885 |
| US-20080200553-A1 | PENTAFLUOROSULFANYLBENZOYLGUANIDINES, PROCESSES FOR THEIR PREPARATION, THEIR USE AS MEDICAMENTS OR DIAGNOSTIC AIDS, AND MEDICAMENTS COMPRISING THEM | TNNI3, TNNT2, SDHB | PTGS2 789/4885AKR1C3 2729/4885AKR1C2 3013/4885 |
| US-20110306670-A1 | PENTAFLUOROSULFANYLBENZOYLGUANIDINES, PROCESSES FOR THEIR PREPARATION, THEIR USE AS MEDICAMENTS OR DIAGNOSTIC AIDS, AND MEDICAMENTS COMPRISING THEM | TNNI3, TNNT2, SDHB | PTGS2 789/4885AKR1C3 2729/4885AKR1C2 3013/4885 |
| US-20030216476-A1 | Pentafluorosulfanylbenzoylguanidines, processes for their preparation, their use as medicaments or diagnostic aids, and medicaments comprising them | TNNI3, TNNT2, SDHB | PTGS2 696/4885AKR1C3 2694/4885AKR1C2 2927/4885 |
| US-20130190290-A1 | Substituted phenylimidazopyrazoles and their use | VHL, FLT4, FLT1 | PTGS2 374/4885AKR1C3 2557/4885AKR1C2 2469/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.